Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
| 323.1 | |
| 327.3 | |
| - | |
| 328.4 | |
| 319.5 | |
| 230.9301-395.8 | |
| 387 022 M | |
| 26.925 | |
| 1 198 M | |
| 148 941 M | |
| -0.34 | |
| 0.0015 | |
| 0.464 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
HYDERABAD (Reuters) - Biopharmaceutical company Biocon Ltd reported a more than six-fold rise in first-quarter profit on Thursday, boosted by a one-time gain from the sale of its Indian branded formul...
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
